Astria Therapeutics Sale to BioCryst Pharmaceuticals Under Investigation
Former Louisiana Attorney General Charles C. Foti, Jr., along with the law firm Kahn Swick & Foti, LLC (KSF), is currently investigating the proposed acquisition of Astria Therapeutics, Inc. (NasdaqGM: ATXS) by BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). This scrutiny focuses on the adequacy of the price offered and the process leading up to this significant corporate transaction.
Details of the Proposed Transaction
According to the terms disclosed, shareholders of Astria Therapeutics are set to receive $8.55 in cash along with 0.59 shares of common stock from BioCryst Pharmaceuticals for each share of Astria they hold. KSF aims to assess whether this proposed valuation fairly reflects the worth of Astria Therapeutics or if it potentially undervalues the company.
Implications for Shareholders and Legal Rights
Shareholders who believe that the offered price undervalues Astria Therapeutics are encouraged to explore their legal options. KSF is offering a no-obligation consultation to discuss these concerns. Interested individuals can reach out to KSF Managing Partner Lewis S. Kahn via email at lewis.kahn@ksfcounsel.com or by calling toll-free at 855-768-1857. More information can also be found on their website at KSF Counsel.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is a law firm known for its expertise in representing shareholders in legal matters regarding corporate transactions. The firm's leadership includes former Louisiana Attorney General Charles C. Foti, Jr., bringing significant legal experience to their investigations and litigations.
Contact Information
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
Website: www.ksfcounsel.com